A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome
Recruiting now
Conditions studied: Schnitzler Syndrome
In brief
The aim of this study is to assess the effectiveness and safety of Ilaris (canakinumab) in clinical use in patients with Schnitzler's syndrome.
Key facts
- Study ID
- NCT07598422
- Run by
- Novartis Pharmaceuticals
- People needed
- 10
- Starts
- 2026-05-13
- Expected to finish
- 2032-06-30
- Last updated by the study team
- 2026-07-01
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients diagnosed with Schnitzler's syndrome using canakinumab for the first time for the indication of Schnitzler's syndrome as described in the package insert.
- Patients starting treatment with canakinumab before conclusion of the contract for this study will also be included in the study so that all patients diagnosed with Schnitzler's syndrome who received canakinumab will be registered in this study.
You may not qualify if…
- Patients previously treated with canakinumab in Study IACT21071.
- All patients treated with canakinumab for the following indications:
- Indications: Cryopyrin-associated periodic syndromes (familial cold autoinflammatory syndrome, Muckle-Wells syndrome, neonatal onset multisystem inflammatory disease), hyper immunoglobulin D (IgD) syndrome (mevalonate kinase deficiency), tumor necrosis factor (TNF) receptor-associated periodic syndrome, familial mediterranean fever, systemic juvenile idiopathic arthritis, adult-onset Still's disease.
- Patients receiving canakinumab for off-label use under the Clinical Trials Act or GCP (e.g., patient-proposed healthcare services, investigator-initiated clinical trial).
Where it is running
- Novartis Investigative Site — Kanoya, Kagoshima-ken, Japan (enrolling)
- Novartis Investigative Site — Osaka, Japan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.